ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Intellia Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -212.59% of over the last 5 years
2
Positive results in Sep 25
- NET SALES(HY) At USD 28.03 MM has Grown at 74.43%
- NET PROFIT(HY) Higher at USD -207.36 MM
- OPERATING PROFIT(Q) Highest at USD -106.54 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 37.59%, its profits have risen by 10.9%
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 37.59% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Intellia Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Intellia Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Intellia Therapeutics, Inc.
42.43%
-0.44
101.45%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-1.59%
EBIT Growth (5y)
-212.59%
EBIT to Interest (avg)
-398.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.11
EV to EBIT
-2.32
EV to EBITDA
-2.39
EV to Capital Employed
4.14
EV to Sales
19.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-178.36%
ROE (Latest)
-58.64%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
NET SALES(HY)
At USD 28.03 MM has Grown at 74.43%
NET PROFIT(HY)
Higher at USD -207.36 MM
OPERATING PROFIT(Q)
Highest at USD -106.54 MM
EPS(Q)
Highest at USD -0.92
-3What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -410.65 MM
RAW MATERIAL COST(Y)
Grown by 10.22% (YoY
Here's what is working for Intellia Therapeutics, Inc.
Net Sales
At USD 28.03 MM has Grown at 74.43%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD -106.54 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Net Profit
Higher at USD -207.36 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.92
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Depreciation
Highest at USD 4.94 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Depreciation
At USD 4.94 MM has Grown at 97.44%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (USD MM)
Here's what is not working for Intellia Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -410.65 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Raw Material Cost
Grown by 10.22% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
